Oric Pharmaceuticals (ORIC) Stock Price, News & Analysis

Company Overview

Oric Pharmaceuticals, Inc. (NASDAQ: ORIC) is a clinical-stage biopharmaceutical company focused on developing therapies for cancer. The company’s research is centered on mechanisms that enable tumors to resist or evade treatment, with the goal of restoring sensitivity to established cancer therapies and improving patient outcomes.

Oric’s pipeline has included investigational small-molecule therapies designed to target cancer biology and treatment resistance. These programs include ORIC-533, an oral inhibitor of CD73 being studied in oncology, and ORIC-944, an oral allosteric inhibitor of EED, a component of the polycomb repressive complex 2. The company has also developed ORIC-114, a brain-penetrant investigational inhibitor directed at selected EGFR and HER2 alterations.

Founded in 2014 and headquartered in South San Francisco, California, Oric Pharmaceuticals conducts research and clinical development activities through collaborations with academic institutions, clinical investigators and other biotechnology or pharmaceutical organizations. Its programs are intended for patients with solid tumors and hematologic malignancies, although the availability and status of specific candidates may change as clinical studies progress.

Key Stats

• Today's Range: $12.17 to $12.93
• 50-Day Range: $10.60 to $14.65
• 52-Week Range: $7.23 to $14.93
• Volume: 1.23 million shs
• Average Volume: 1.48 million shs
• Market Capitalization: $1.26 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.18
• Consensus Rating: Moderate Buy

Oric Pharmaceuticals Stock Analysis - MarketRank™

Oric Pharmaceuticals scored higher than 43% of companies evaluated by MarketBeat, and ranked 606th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Oric Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on no strong buy ratings, 13 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Oric Pharmaceuticals has a consensus price target of $20.18, representing about 65.4% upside from its current price of $12.20.

Amount of Analyst Coverage

Oric Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Oric Pharmaceuticals are expected to decrease in the coming year, from ($1.53) to ($1.75) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Oric Pharmaceuticals is -9.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Oric Pharmaceuticals is -9.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Oric Pharmaceuticals has a P/B Ratio of 3.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.94% of the float of Oric Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Oric Pharmaceuticals has a short interest ratio ("days to cover") of 14.21, which indicates bearish sentiment.

Change versus previous month

Short interest in Oric Pharmaceuticals has recently increased by 1.54%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Oric Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Oric Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.55

News Sentiment

Oric Pharmaceuticals has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Oric Pharmaceuticals this week, compared to 4 articles on an average week.

Search Interest

2 people have searched for ORIC on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Oric Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Oric Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,243,532.00 in company stock.

Percentage Held by Insiders

5.70% of the stock of Oric Pharmaceuticals is held by insiders.

Percentage Held by Institutions

95.05% of the stock of Oric Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/03/2026
• Today: 10/03/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ORIC
• CIK: 1796280
• Web: www.oricpharma.com
• Phone: 650-388-5600
• Fax: N/A
• Employees: 111
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Oric Pharmaceuticals: $20.18
• High Price Target: $27.00
• Low Price Target: $14.00
• Potential Upside/Downside: +65.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.35)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$129.47 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -35.35%
• Return on Assets: -33.39%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.19
• Quick Ratio: 13.19

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.90 per share
• Price / Book: 3.13

Miscellaneous

• Outstanding Shares: 103,653,000
• Free Float: 97,745,000
• Market Cap: $1.26 billion
• Optionable: Optionable
• Beta: 0.99